We are live on ! Find out more

3,196 hedge funds and large institutions have $196B invested in Pfizer in 2022 Q1 according to their latest regulatory filings, with 157 funds opening new positions, 1,379 increasing their positions, 1,343 reducing their positions, and 183 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more repeat investments, than reductions

Existing positions increased: 1,379 | Existing positions reduced: 1,343

0.14% less ownership

Funds ownership: 67.38%67.24% (-0.14%)

2% less call options, than puts

Call options by funds: $3.18B | Put options by funds: $3.23B

2% less funds holding

Funds holding: 3,2633,196 (-67)

12% less capital invested

Capital invested by funds: $222B → $196B (-$25.8B)

14% less first-time investments, than exits

New positions opened: 157 | Existing positions closed: 183

34% less funds holding in top 10

Funds holding in top 10: 250166 (-84)

Holders
3,196
Holders Change
-67
Holders Change %
-2.05%
% of All Funds
50.4%
Holding in Top 10
166
Holding in Top 10 Change
-84
Holding in Top 10 Change %
-33.6%
% of All Funds
2.62%
New
157
Increased
1,379
Reduced
1,343
Closed
183
Calls
$3.18B
Puts
$3.23B
Net Calls
-$53.7M
Net Calls Change
-$131M
Name Holding Trade Value Shares
Change
Change in
Stake
Man Group
151
Man Group
United Kingdom
$117M +$87.2M +1,680,347 +293%
UIM
152
USS Investment Management
United Kingdom
$114M +$3.72M +71,693 +3%
SC
153
Scotia Capital
Ontario, Canada
$112M +$1.19M +22,925 +1%
Handelsbanken Fonder
154
Handelsbanken Fonder
Sweden
$111M -$9.06M -174,531 -8%
DZ Bank
155
DZ Bank
Germany
$110M -$527M -10,157,575 -83%
Jane Street
156
Jane Street
New York
$110M -$59.9M -1,154,696 -35%
Lazard Asset Management
157
Lazard Asset Management
New York
$108M +$66.2M +1,275,423 +158%
SAM
158
Silvercrest Asset Management
New York
$108M +$1.23M +23,694 +1%
Osaic Holdings
159
Osaic Holdings
Arizona
$107M -$4.24M -81,683 -4%
ZIM
160
Zacks Investment Management
Illinois
$104M +$4.75M +91,496 +5%
PCA
161
Personal Capital Advisors
California
$103M +$10.1M +194,905 +11%
ZIG
162
Zurich Insurance Group
Switzerland
$103M +$103M +1,981,090 New
NFC
163
Northeast Financial Consultants
Connecticut
$102M +$19.9M +383,242 +24%
Royal London Asset Management
164
Royal London Asset Management
United Kingdom
$102M +$3.94M +75,957 +4%
SSM
165
Sound Shore Management
Connecticut
$102M -$18.1M -348,776 -15%
LBA
166
Letko, Brosseau & Associates
Quebec, Canada
$100M -$5.32M -102,480 -5%
MIFH
167
Migdal Insurance & Financial Holdings
Israel
$99.6M +$423K +8,150 +0.4%
RPI
168
Railway Pension Investments
United Kingdom
$95.6M +$30.9M +594,600 +48%
VRS
169
Virginia Retirement Systems
Virginia
$95.5M +$32.3M +622,900 +51%
ORIO
170
Old Republic International (ORI)
Illinois
$94.8M -$2.33M -45,000 -2%
Pacer Advisors
171
Pacer Advisors
Pennsylvania
$93.5M +$55.4M +1,066,899 +144%
Nisa Investment Advisors
172
Nisa Investment Advisors
Missouri
$91.4M -$3.09M -59,505 -3%
HPC
173
HM Payson & Co
Maine
$90.1M +$3.31M +63,874 +4%
Calamos Advisors
174
Calamos Advisors
Illinois
$89.7M +$9.48M +182,747 +12%
Aberdeen Group
175
Aberdeen Group
United Kingdom
$89.2M -$57.6M -1,110,387 -39%

PFE Hedge Fund Activity: Q1 2022 in Review

3,196 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q1 2022, worth a combined $196B — down 12% from $222B a quarter earlier.

Sellers outnumbered buyers: 183 funds closed out of PFE and 157 opened new positions — a net loss of 26 holders — while 1,343 trimmed existing stakes and 1,379 added.

The largest buyer was Capital International Investors, adding an estimated $1.94B. The largest seller was Franklin Resources, cutting an estimated $923M.

  • 3,196 institutional investors held Pfizer (PFE) as of Q1 2022, down from 3,263 in Q4 2021.
  • Funds reported $196B of Pfizer stock for Q1 2022, down 12% quarter-over-quarter.
  • 157 funds opened new Pfizer positions in Q1 2022 and 183 closed out, a net change of -26 holders.
  • The largest Pfizer buyer in Q1 2022 was Capital International Investors, an estimated $1.94B added.
  • The largest Pfizer seller in Q1 2022 was Franklin Resources, an estimated $923M sold.

Based on aggregated 13F filings for Q1 2022.